Evidence map›Paper›PMID 36534128›Full record

ArticleBlood advances2023

Safe and efficient lentiviral vector integration with HSC-targeted gene therapy.

Stefan Radtke, Dnyanada Pande, Mark Enstrom, Hans-Peter Kiem

Abstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Stefan RadtkeStem Cell and Gene Therapy Program, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0002-2842-4820
Dnyanada PandeStem Cell and Gene Therapy Program, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0001-9343-0584
Mark EnstromStem Cell and Gene Therapy Program, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Hans-Peter KiemStem Cell and Gene Therapy Program, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0001-5949-4947

Funding

Novel Gene Editing Approaches for HemoglobinopathiesR01HL136135 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HANS-PETER KIEM · 2017 to 2026
$7.7M
Targeting a Novel Hematopoietic Stem Cell Population in Non-Human Primates for Effective and Sustained Gene TherapyR01AI135953 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KIEM, HANS-PETER · 2018 to 2022
$4.5M
NHLBI NIH HHS R01 HL136135NIAID NIH HHS R01 AI135953
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Genetic TherapyLentivirus

Identifiers

PMID36534128
PMCPMC10480530

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.